Stay updated on CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial
Sign up to get notified when there's something new on the CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial page.

Latest updates to the CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded MedlinePlus Genetics topic on schizophrenia to the page. No deletions were found.SummaryDifference0.1%

- Check20 days agoChange DetectedMajor update to page status notice and version; removal of a genetics topic balanced by an explicit operating-status message and version bump.SummaryDifference3%

- Check27 days agoChange DetectedUpdated topics: adding schizophrenia coverage under MedlinePlus and MedlinePlus Genetics; removing broader or separate drug safety categories; version updated from v3.0.2 to v3.1.0.SummaryDifference0.5%

- Check34 days agoChange DetectedAdded results timing, detailed Emraclidine dose arms (10 mg and 30 mg), comprehensive PANSS/CGI endpoints, safety measures, and regulatory identifiers; removed some older measures and terminology.SummaryDifference49%

- Check42 days agoChange DetectedPage revision updated to v3.0.2, replacing v3.0.1; and the 'Back to Top' element was removed.SummaryDifference0.2%

- Check49 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.SummaryDifference0.2%

Stay in the know with updates to CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial page.